ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - trastuzumab - stomach neoplasms; breast neoplasms - antineoplastična sredstva - grudi cancermetastatic grudi cancerogivri indiciran za liječenje odraslih bolesnika s her2 pozitivnim metastatskih tumora dojke (mbk):u monoterapiji za liječenje onih pacijenata koji su primili najmanje dva načina kemoterapije za метастатической bolesti. prije kemoterapije moraju biti uključena barem антрациклина i таксана, ako pacijenti nisu prikladni za tih postupaka. hormon-receptor-pozitivnih bolesnika također mora biti hormonske terapije, ako pacijenti nisu prikladni za tih treatmentsin kombinaciji s паклитакселом za liječenje onih pacijenata koji nisu primili kemoterapiju za метастатической bolesti i za koga антрациклиновый ne suitablein kombinaciju sa docetaxel za liječenje bolesnika koji nisu primali kemoterapiju za метастатической bolesti kombinaciji s inhibitor aromataze za liječenje pacijenata u postmenopauzi s hormon-receptor pozitivnim ГБЦ, ne ranije liječenih трастузумаб. ranog raka dojke ogivri indiciran za liječenje odraslih bolesnika s her2 pozitivnim ranog raka dojke (ЕДК):nakon operacije, kemoterapije (неоадъювантной ili adjuvantne) i radioterapije (ako je primjenjivo)nakon adjuvantne kemoterapije doksorubicin i ciklofosfamid, u kombinaciji s паклитакселом ili docetaxelin kombinaciji s adjuvantne kemoterapije, koji se sastoji od доцетаксела i карбоплатина. u kombinaciji s неоадъювантной kemoterapije, nakon čega slijedi ogivri adjuvantne terapije, lokalno (uključujući i upalne bolesti ili tumora > 2 cm u promjeru. ogivri treba koristiti samo u bolesnika s metastaze ili ebc tumora čije je bilo her2 i гиперэкспрессии ili амплификации gena her2, kako se određuje točan i dokazani анализами. Метастатические cancerogivri želuca u kombinaciji s Капецитабин ili 5-фторурацилом i цисплатином indiciran za liječenje odraslih bolesnika s her2 pozitivnog метастатического raka želuca ili пищеводно-želučani tranzicije, koji nisu primili do противоопухолевое liječenje bolesti метастатической. ogivri treba koristiti samo u bolesnika s metastaze raka želuca (lecs), bolesti koje imaju гиперэкспрессию her2 i kako se određuje ihc2+ i prateću СИШ ili rezultat ribom, ili igh 3+ rezultat. treba koristiti točne i dokazane metode analize .

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - inzulin aspart - Šećerna bolest - lijekovi koji se koriste u dijabetesu - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

orexigen therapeutics ireland limited - bupropion hidroklorid, naltrexone hydrochloride - obesity; overweight - pripravci protiv pretilosti, isključujući. prehrambeni proizvodi - mysimba drugačije, kao dodatak гипокалорийной prehrana i povećana tjelesna aktivnost, za kontrolu tjelesne težine kod odraslih bolesnika (≥18 godina) s - indeks tjelesne mase (bmi)≥ 30 kg/m2 (pretilost) ili≥ 27 kg/m2 i < 30 kg/m2 (težine) ako imate jedan ili više težine, srodne bolesti (e. tip 2 dijabetes, dislipidemija, ili kontrolirano arterijska hipertenzija)tretman s mysimba treba biti zaustavljen nakon 16 tjedana, ako je pacijent izgubio od najmanje 5% od početne tjelesne mase .

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

bausch health ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - fosinoprilnatrij hidroklorotiazid - tableta - 20 mg + 12,5 mg - urbroj: 1 tableta sadrži 20 mg fosinoprilnatrija i 12,5 mg hidroklorotiazida

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

bausch health ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - diklofenaknatrij - želučanootporna kapsula, tvrda - 75 mg - urbroj: jedna tvrda želučanootporna kapsula sadrži 75 mg diklofenaknatrija

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

bausch health ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - fosinoprilnatrij - tableta - 10 mg - urbroj: jedna tableta sadrži 10 mg fosinoprilnatrija

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

bausch health ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - fosinoprilnatrij - tableta - 20 mg - urbroj: jedna tableta sadrži 20 mg fosinoprilnatrija

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

bausch health ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - diklofenaknatrij - kapsula s prilagođenim oslobađanjem, tvrda - 75 mg - urbroj: jedna kapsula sadrži 75 mg diklofenaknatrija (25 mg u obliku želučanootpornih peleta i 50 mg u obliku peleta s produljenim oslobađanjem)

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

theramex ireland limited - linzagolix choline - uterusa - hipofiza i hipotalamusni hormoni i analozi - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.